Guestimating that anything like 5000 RG procedures a year would make PLC "a real company." That could happen in Italy alone. It might be possible to get an almost-adequate selling effort going in Italy by year end.
PLC remains too small and weak to do the needful stuff quickly. The trend seems to be our friend now, but it'll be hard for it to get steeply positive. And if I was Mr J&J, I would not be enthusiastic about making a bid high enough to excite shareholders until after there was clinical experience on RG "in the wild."